IRIDEX (IRIX) News
NASDAQ: IRIXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
0.4449-0.0214 (-4.59%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRIX news summary
We found 6 recent headlines mentioning IRIDEX (IRIX): 3 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, IRIX is down 4.59% at $0.4449. The most recent story, "IRIDEX (IRIX) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest IRIDEX headlines
- IRIDEX (IRIX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- IRIDEX Corporation Reports Third Quarter 2026 Revenue of $10.2 million and Lowers Full Year GuidanceIRIDEX Corporation reported its financial results for the third quarter ended October 3, 2026, generating total revenue of $10.2 million, compared to $12.5 million in the prior year period. The…NasdaqIRIX, SUN
- Iridex Reports Third Quarter 2026 Financial ResultsSAN JOSE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the…GlobeNewswire
- Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026SAN JOSE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the…GlobeNewswire
- Iridex Reports Sustained Glaucoma Benefits With MicroPulse Laser Therapy At Two Years(RTTNews) - Iridex Corporation (IRIX) announced the publication of a two-year independent clinical study reporting sustained reductions in intraocular pressure (IOP) and a lower medication burden…NasdaqIRIX, ET
- Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced GlaucomaStudy reports sustained IOP reduction and reduced medication burden over 24 months Study reports sustained IOP reduction and reduced medication burden over 24 monthsGlobeNewswire